Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we spot heart damage early during breast cancer therapy?

NCT ID NCT07588425

Knowledge-focused Sponsor: Fatih GURLER Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study follows 100 women with early-stage breast cancer who are receiving standard chemotherapy or anti-HER2 therapy. Researchers will use heart ultrasounds and blood tests to look for early signs of heart damage. The goal is to find better ways to detect cardiac side effects before they become serious.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors detect heart damage earlier during breast cancer treatment, potentially preventing long-term heart problems.
What could go wrong
This is an observational study, not testing a new treatment. It may not lead to changes in care, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult women with histologically confirmed Stage I-III breast cancer for whom neoadjuvant or adjuvant systemic therapy (chemotherapy and/or HER2-targeted therapy) is planned, recruited from the Medical Oncology outpatient clinic at Gazi University Faculty of Medicine Hospital, Ankara, Türkiye.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of breast cancer * Stage I, II, or III disease * Planned neoadjuvant or adjuvant chemotherapy and/or HER2-targeted systemic therapy * Baseline transthoracic echocardiographic left ventricular ejection fraction (LVEF) ≥ 50% * Age ≥ 18 years * Able and willing to provide written informed consent Exclusion Criteria: * Metastatic (Stage IV) breast cancer * Pre-existing heart failure or clinically significant cardiac disease * Prior exposure to chemotherapy or other cardiotoxic systemic therapy * Concurrent active malignancy other than breast cancer * Inability or unwillingness to comply with the planned follow-up and assessment schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer (early breast cancer) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer (early breast cancer) Cancer therapy-related cardiac dysfunction Cardiotoxicity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gazi University Faculty of Medicine

    RECRUITING

    Ankara, Ankara, 06560, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.